Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study

被引:44
作者
Palabrica, Frances Rose R. [1 ]
Kwong, Shirley L. [1 ]
Padua, Florecita R. [1 ]
机构
[1] Dr Fe Mundo Med Ctr, Allergy Asthma & Immunol Unit, 11 Banawe St, Quezon City 1100, Metro Manila, Philippines
关键词
Intravenous immunoglobulins; Retrospective study; Side effects;
D O I
10.5415/apallergy.2013.3.4.249
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Intravenous immunoglobulin (IVIG) is a biological product with adverse effects that appears to vary considerably among different IVIG preparations. Objectives: To describe the adverse events of patients given intravenous immunoglobulin infusions. Method: Data was collected on all patients receiving IVIG infusion at a tertiary hospital from January 2001 to December 2010. Descriptive statistics was used. Results: 77 patients (45 males, 32 females) received IVIG infusions. Thirty two percent (n = 25) experienced adverse reactions. The most common indication was Kawasaki disease (85.7%) followed by immunodeficiency disorders (7.8%). Majority of the patients were children, with the highest frequency of infusions among those aged 2 to 8 years old (52%). 36 infusions were associated with occurrence of adverse effects. Fever was the most common adverse event (n = 11, 30.6%), followed by rash (n = 8, 22.2%) and chills (n = 7, 19.4%). Other adverse events were cyanosis (n = 3, 8.3%), hypotension (n = 2, 5.6%), hypothermia (n = 2, 5.6%), irritability (n = 1, 2.8%), vomiting (n = 1, 2.8%), and chest pain (n = 1, 2.8%). Adverse events were observed to occur most frequently within 1 to 6 h from onset of IVIG infusion. Among the various IVIG preparations available locally (Gammagard, Kiovig, Gamimune, Veno-S & IV Globulin S), Gammagard was the brand frequently used (50.7%). It also has the most number of adverse events, with 17 out of 41 (41.5%) infusions resulting in adverse reactions. Most of the reactions occurred with fast infusion rates, and clinical manifestations subsided when the rate of infusion was reduced. Conclusion: In this study, thirty two percent of patients given IVIG infusions experienced adverse events. Fever was the most common manifestation. Symptoms occurred within 1 to 6 h from onset of infusion, were affected by fast infusion rates, and managed by reducing the rate of infusion.
引用
收藏
页码:249 / 256
页数:8
相关论文
共 10 条
[1]  
Alejandria MM, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001090
[2]   The IgG molecule as a biological immune response modifier: Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders [J].
Ballow, Mark .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) :315-323
[3]  
Dashti-Khavidaki S, 2009, J INVEST ALLERG CLIN, V19, P139
[4]  
DUHEM C, 1994, CLIN EXP IMMUNOL, V97, P79
[5]  
IVIG Guideline Development Group of the IVIG Expert Group, 2008, CLIN GUID US INTR IM
[6]   Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy [J].
Lemm, G .
NEUROLOGY, 2002, 59 (12) :S28-S32
[7]  
Purisima BC, 2009, PHILIPP J PEDIATR, V57, P11
[8]  
Scheinfeld NS, 1994, INTRAVENOUS IMMUNOGL
[9]   A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions [J].
Singh-Grewal, D. ;
Kemp, A. ;
Wong, M. .
ARCHIVES OF DISEASE IN CHILDHOOD, 2006, 91 (08) :651-654
[10]  
Stiehm ER OH, 2004, IMMUNOLOGICAL DISORD, P289